Concepedia

Publication | Open Access

Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States

DOIFull Paper Access

123

Citations

38

References

2016

Year

William V. Padula, Richard A. Larson, Stacie B. Dusetzina, Jane F. Apperley, Rüdiger Hehlmann, Michele Baccarani, Ekkehard Eigendorff, Joëlle Guilhot, François Guilhot, Rüdiger Hehlmann,
JNCI Journal of the National Cancer Institute

Abstract

When imatinib loses patent protection and its price declines, its use will be the cost-effective initial treatment strategy for CML-CP.

References

YearCitations

Page 1